ATRS Antares Pharma Inc.

Antares Pharma Enters Exclusive License Agreement With Ferring Pharmaceuticals for Nocdurna® in U.S.

Antares Pharma Enters Exclusive License Agreement With Ferring Pharmaceuticals for Nocdurna® in U.S.
EN
01/10/2020

Underlying

ATRSAntares Pharma Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Antares Pharma Inc.

 PRESS RELEASE
Free
ATRS Antares Pharma ...

Antares Pharma Announces FDA Approval Of TLANDO™, an Oral Treatment fo...

Antares Pharma Announces FDA Approval Of TLANDO™, an Oral Treatment for Testosterone Replacement Therapy Commercial launch expected in 2Q 2022 EWING, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration granted final approval for TLANDO™ (testosterone undecanoate), an oral treatment for testosterone replacement therapy (“TRT”) indicated for conditions associated with a deficiency or absence of endogenous testosterone, or hypogonadism in adult males. Ro...

March 29, 2022 1 EN
 PRESS RELEASE
Free
ATRS Antares Pharma ...

Antares Pharma Reports Fourth Quarter and Full-Year 2021 Financial and...

Antares Pharma Reports Fourth Quarter and Full-Year 2021 Financial and Operating Results Full-Year 2021 Revenue Increased 23% Year-Over-Year to $184.0 Million Full-Year 2021 Net Income of $46.3 Million, or $0.26 Per Diluted Earnings Per Share Full-Year 2021 Adjusted EBITDA of $39.2 Million 2022 Revenue Guidance Range of $200 to $220 Million EWING, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today reported financial and operating results for the fourth quarter ended December 31, 2021 with record reven...

March 3, 2022 1 EN
 PRESS RELEASE
Free
ATRS Antares Pharma ...

Antares Pharma to Present at the Cowen 42nd Annual Healthcare Conferen...

Antares Pharma to Present at the Cowen 42nd Annual Healthcare Conference EWING, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to virtually present and host investor meetings at the Cowen 42nd Annual Healthcare Conference being held on March 7-9, 2022. Details of the presentation are as follows: Event:  Cowen 42nd Annual Healthcare ConferenceFormat:  Fireside Chat and 1x1 MeetingsPresentation Date: Tuesday, March ...

February 28, 2022 1 EN
 PRESS RELEASE
Free
ATRS Antares Pharma ...

Antares Pharma To Report Fourth Quarter And Full-Year 2021 Financial A...

Antares Pharma To Report Fourth Quarter And Full-Year 2021 Financial And Operating Results EWING, N.J., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced it will release its fourth quarter and full-year 2021 financial and operating results on Thursday, March 3, 2022, before the market opens. Antares will host a conference call on Thursday, March 3, 2022 at 8:30am ET to discuss the results. The dial-in numbers are (888) 254-3590 for domestic callers and (323) 794-2551 for international callers. The co...

February 17, 2022 1 EN
 PRESS RELEASE
Free
ATRS Antares Pharma ...

Antares Pharma Announces FDA Acceptance of NDA Resubmission for TLANDO...

Antares Pharma Announces FDA Acceptance of NDA Resubmission for TLANDO® PDUFA target action date set for March 28, 2022 EWING, N.J., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted its New Drug Application (“NDA”) resubmission for TLANDO® (testosterone undecanoate), an oral treatment for testosterone replacement therapy (“TRT”). The FDA designated the NDA as a Class 1 resubmission with a two-month review goal period and set a target a...

February 3, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch